Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 320

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 320
---
 in a currency other than the functional currency are translated at the period-end exchange rate. Unrealized gains and losses arising from translation are recognized in net operating income.

Foreign exchange gains and losses arising from the translation of inter-Group transactions or receivables or payables denominated in currencies other than the functional currency of the entity are recognized in the line “net financial income (loss)” of the consolidated statements of income (loss).

Foreign currency transactions are translated into the presentation currency using the following exchange rates:

                    December 31, 2022                        December 31, 2023                        December 31, 2024                    
  €1 EQUALS TO      AVERAGE RATE           CLOSING RATE      AVERAGE RATE           CLOSING RATE      AVERAGE RATE           CLOSING RATE  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  USD               1.0530                 1.0666            1.0813                 1.1050            1.0824                 1.0389        

F-21

f)Consolidation method

The Group applies IFRS 10 Consolidated financial statements. IFRS 10 presents a single consolidation model identifying control as the criteria for consolidating an entity. An investor controls an investee if it has the power over the entity, is exposed or has rights to variable returns from its involvement with the entity and has the ability to use its power over the entity to affect the amount of the investor’s returns. Subsidiaries are entities over which the Company exercises control. They are fully consolidated from the date the Group obtains control and are deconsolidated from the date the Group ceases to exercise control. Intercompany balances and transactions are eliminated.

g)Financial instruments

Financial assets

Financial assets are initially measured at fair value plus directly attributable transaction costs in the case of instruments not measured at fair value through profit or loss. Directly attributable transaction costs of financial assets measured at fair value through profit or loss are recorded in the consolidated statement of income (loss).

Under IFRS 9, financial assets are classified in the following three categories:

• Financial assets at amortized cost;

• Financial assets at fair value through other comprehensive income (“ FVOCI”); and

• Financial assets at fair value through profit or loss.

The classification of financial assets depends on:

• The characteristics of the contractual cash flows of the financial assets; and

• The business model that the entity follows